Insmed Incorporated (FRA:IM8N)
Germany · Delayed Price · Currency is EUR | Market Cap | 23.53B +0.3% |
| Revenue (ttm) | 995.77M +185.8% |
| Net Income | -766.16M |
| EPS | -3.58 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 107.62 |
| Previous Close | 106.80 |
| Day's Range | 107.62 - 108.46 |
| 52-Week Range | 78.77 - 185.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Insmed announces Japan’s MHLW approves Brinsupri
Insmed (INSM) announced that Japan’s Ministry of Health, Labour and Welfare has approved Brinsupri, an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and pediatric patient...
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER,...
Insmed price target raised to $195 from $185 at Truist
Truist raised the firm’s price target on Insmed (INSM) to $195 from $185 and keeps a Buy rating on the shares. The firm cites the company’s strong Q2 results, driven…
Insmed price target lowered to $175 from $179 at JPMorgan
JPMorgan lowered the firm’s price target on Insmed (INSM) to $175 from $179 and keeps an Overweight rating on the shares.
Insmed price target raised to $218 from $212 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Insmed (INSM) to $218 from $212 and keeps an Overweight rating on the shares.
Insmed price target raised to $170 from $160 at Evercore ISI
Evercore ISI raised the firm’s price target on Insmed (INSM) to $170 from $160 and keeps an Outperform rating on the shares.
Insmed price target lowered to $205 from $207 at Guggenheim
Guggenheim lowered the firm’s price target on Insmed (INSM) to $205 from $207 and keeps a Buy rating on the shares.
Insmed price target raised to $172 from $166 at UBS
UBS raised the firm’s price target on Insmed (INSM) to $172 from $166 and keeps a Buy rating on the shares. Insmed delivered a strong Q2 beat and raised guidance,…
Insmed price target raised to $169 from $161 at Wells Fargo
Wells Fargo raised the firm’s price target on Insmed (INSM) to $169 from $161 and keeps an Overweight rating on the shares. The firm is impressed with the Brinsupri launch,…
Insmed price target raised to $175 from $160 at Jefferies
Jefferies raised the firm’s price target on Insmed (INSM) to $175 from $160 and keeps a Buy rating on the shares. A “strong” Q2 beat supports the FY26 guidance raise…
Insmed Earnings Call Transcript: Q2 2026
Q2 2026 saw record BRINSUPRI growth, with revenue up 49% sequentially and new patient starts exceeding expectations. Full-year guidance for BRINSUPRI was raised to $1.25–$1.4B, and peak sales estimates for key assets increased, while cash flow positivity is expected in 2027.
Insmed Quarterly report: Q2 2026
Insmed has published its Q2 2026 quarterly earnings report on August 6, 2026.
Insmed Earnings release: Q2 2026
Insmed released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Insmed Slides: Q2 2026
Insmed has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Insmed reports Q2 EPS (6c) vs. ($1.70) last year
Reports Q2 revenue $425.5M, consensus $393.36M. “Our team delivered tremendous results in the second quarter of the year, reflecting our operational excellence and positioning for the future,” said Wi...
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
—Total Company Revenues of $425.5 Million for the Second Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Qua...
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed initiated with an Outperform at BMO Capital
BMO Capital analyst Conor MacKay initiated coverage of Insmed (INSM) with an Outperform rating and $192 price target The firm’s positive view is based on Brinsupri’s rapid launch in NCFB,…
Insmed Transcript: Study result
The 12-month open-label extension of TPIP in PAH patients showed sustained and clinically meaningful improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved asymptomatic status, and 65% reached refined low-risk, supporting TPIP's potential as a leading PAH therapy.
Insmed Press release: Study result
Insmed issued a press release on July 16, 2026, disclosing material business information to investors.
Insmed Slides: Study result
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2026.
Insmed’s inhalation powder shows efficacy and safety in arterial hypertension
Insmed (INSM) announced positive 12-Month data from the ongoing open-label extension study evaluating treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmona...
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
– 12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated...